CA2436311A1 - Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda - Google Patents

Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda Download PDF

Info

Publication number
CA2436311A1
CA2436311A1 CA002436311A CA2436311A CA2436311A1 CA 2436311 A1 CA2436311 A1 CA 2436311A1 CA 002436311 A CA002436311 A CA 002436311A CA 2436311 A CA2436311 A CA 2436311A CA 2436311 A1 CA2436311 A1 CA 2436311A1
Authority
CA
Canada
Prior art keywords
nmda receptor
receptor antagonist
day
human patient
antagonist compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002436311A
Other languages
English (en)
Inventor
Stuart Lipton M.D.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamas Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2436311A1 publication Critical patent/CA2436311A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des méthodes de traitement d'un patient humain atteint d'un trouble neuropsychiatrique. L'invention concerne plus particulièrement des compositions et des méthodes qui modulent ou antagonisent l'activité des récepteurs neuronaux de NMDA. Cette activité antagoniste peut moduler la réaction excitatrice des neurones induite par le glutamate, ce qui inhibe un effet excitotoxique, produit un effet neurotrophique, et induit un effet thérapeutique pouvant traiter le trouble neuropsychiatrique.
CA002436311A 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda Abandoned CA2436311A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25400700P 2000-12-07 2000-12-07
US60/254,007 2000-12-07
PCT/US2001/048516 WO2002045710A1 (fr) 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda

Publications (1)

Publication Number Publication Date
CA2436311A1 true CA2436311A1 (fr) 2002-06-13

Family

ID=22962564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002436311A Abandoned CA2436311A1 (fr) 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda

Country Status (8)

Country Link
EP (1) EP1351670A4 (fr)
JP (1) JP2004515477A (fr)
CN (1) CN1486180A (fr)
AU (1) AU2002229056A1 (fr)
BR (1) BR0116001A (fr)
CA (1) CA2436311A1 (fr)
MX (1) MXPA03005130A (fr)
WO (1) WO2002045710A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8246671B2 (en) 1999-08-09 2012-08-21 Cardiokinetix, Inc. Retrievable cardiac devices
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US8039009B2 (en) * 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
WO2006138227A1 (fr) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Formulation de gouttes de memantine a liberation modifiee et immediate
EP1986735A4 (fr) 2006-02-06 2011-06-29 Northwind Ventures Systèmes et procédés de réduction de volume
KR101333753B1 (ko) * 2006-04-13 2013-11-28 주식회사 아라온테크 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물
IT1396556B1 (it) 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
JP5875986B2 (ja) 2009-10-26 2016-03-02 カーディオキネティックス・インコーポレイテッドＣａｒｄｉｏｋｉｎｅｔｉｘ， Ｉｎｃ． 心室容積縮小
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
JP5562716B2 (ja) 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
PT3137658T (pt) * 2014-04-30 2022-05-05 Univ Nat Taiwan Uso de compostos conhecidos como inibidores do d-aminoácido oxidase
CN105294450B (zh) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
CN106852115A (zh) 2014-09-28 2017-06-13 卡迪欧凯尼迪克斯公司 用于治疗心功能不全的装置
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
AU2018309710A1 (en) * 2017-08-01 2020-02-27 Stuart A. Lipton Methods and compositions for treating neurological conditions
EP3713558A4 (fr) * 2017-11-22 2021-10-13 Panorama Research Inc. Composés de nitrate d'aminoadamantyle et leur utilisation pour traiter des troubles du système nerveux central
CN109206317B (zh) * 2018-09-12 2021-07-09 青岛海蓝医药有限公司 一种金刚烷胺类硝酸酯衍生物的制备工艺
CN110938006A (zh) * 2019-12-04 2020-03-31 重庆植恩药业有限公司 盐酸美金刚杂质c的制备方法
CN114544826B (zh) * 2020-11-24 2023-12-08 重庆医科大学 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584718A (ja) * 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents

Also Published As

Publication number Publication date
JP2004515477A (ja) 2004-05-27
WO2002045710A1 (fr) 2002-06-13
AU2002229056A1 (en) 2002-06-18
MXPA03005130A (es) 2004-12-06
WO2002045710A9 (fr) 2003-04-24
BR0116001A (pt) 2004-07-06
CN1486180A (zh) 2004-03-31
EP1351670A1 (fr) 2003-10-15
EP1351670A4 (fr) 2004-07-07

Similar Documents

Publication Publication Date Title
US20100137448A1 (en) Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists
CA2436311A1 (fr) Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda
Taksande et al. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine
US20060270742A1 (en) Compositions and methods for the treatment of neurodegenerative diseases
US20120156139A1 (en) Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders
TW200808696A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
JP2009501224A (ja) 神経保護の方法
US20140371229A1 (en) New therapeutic approaches for treating parkinson's disease
AU4967399A (en) Method for the treatment of insomnia
JP2007513169A (ja) 自殺傾向を予防しまたは減少させるための、および自殺傾向に関連する大うつ病を治療するためのメマンチン
AU2006235400A1 (en) Method of treating schizophrenia prodrome
Tutakhail et al. Neuropathology of kynurenine pathway of tryptophan metabolism
RU2630583C2 (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
AU2741600A (en) Method for the treatment of incontinence
US20050096395A1 (en) Methods of treating attention deficit/hyperactivity disorder (adhd)
AU2007203426B2 (en) Methods for treating neuropsychiatric disorders with NMDA receptor antagonists
EP1852113A2 (fr) Methodes pour le traitement des maladies neuropsychiatriques avec des antagonistes du recepteur
Matveychuk et al. Comparison of phenelzine and geometric isomers of its active metabolite, β-phenylethylidenehydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine
Piletz et al. Putative agmatinase inhibitor for hypoxic-ischemic new born brain damage
WO2011008675A2 (fr) Composés de catécholamine, compositions, et formulations, et méthodes pour les utiliser
JP2008540458A (ja) 治療活性を有するダイヤモンドイド誘導体
Hilton et al. Simultaneous glutamate and GABAA receptor agonist administration increases calbindin levels and prevents hippocampal damage induced by either agent alone in a model of perinatal brain injury
WO2023233329A1 (fr) Utilisation de 5-méthoxy-2-aminoindane ("meai") dans des méthodes de traitement de la dépendance à la cocaïne
WO2023215342A1 (fr) Compositions et procédés de traitement de la névralgie du trijumeau
Vender et al. MonthlyUpdate—Central & Peripheral Nervous Systems: Pharmacotherapeutic Potential for Compounds Acting at NMDA Receptors: Update 1995

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead